Daniel L Bohl
Overview
Explore the profile of Daniel L Bohl including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
397
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cheng X, Bohl D, Storch G, Ryschkewitsch C, Gaudreault-Keener M, Major E, et al.
J Am Soc Nephrol
. 2011 Apr;
22(5):825-31.
PMID: 21511831
BK and JC polyomaviruses can reactivate after transplantation, causing renal dysfunction and graft loss. The incidence of JC reactivation after renal transplant is not well understood. Here, we characterized JC...
2.
Bohl D, Brennan D, Ryschkewitsch C, Gaudreault-Keener M, Major E, Storch G
J Clin Virol
. 2008 Aug;
43(2):184-9.
PMID: 18676176
Background: The mean urine BK viral load in kidney transplant recipients increases with the intensity of infection as the infection progresses from transient viruria to sustained viremia. Objectives: This study...
3.
Bohl D, Brennan D
Clin J Am Soc Nephrol
. 2007 Sep;
2 Suppl 1:S36-46.
PMID: 17699509
Nephropathy from BK virus (BKV) infection is an evolving challenge in kidney transplant recipients. It is the consequence of modern potent immunosuppression aimed at reducing acute rejection and improving allograft...
4.
Bohl D, Storch G, Ryschkewitsch C, Gaudreault-Keener M, Schnitzler M, Major E, et al.
Am J Transplant
. 2005 Aug;
5(9):2213-21.
PMID: 16095500
In a previous study, we performed serial BK virus (BKV), polymerase chain reaction (PCR) and detected active BKV infection in 70 (35.4%) of 198 renal transplant recipients. In the current...
5.
Hardinger K, Bohl D, Schnitzler M, Lockwood M, Storch G, Brennan D
Transplantation
. 2005 Jul;
80(1):41-6.
PMID: 16003231
Background: To date, the clinical trials of tacrolimus (TAC) versus cyclosporine modified (CsA), have not defined which agent is more cost-effective for immunosuppression in renal transplant recipients especially in a...
6.
Khoury J, Bohl D, Hersh M, Argoudelis A, Brennan D
Am J Kidney Dis
. 2005 Apr;
45(5):926-9.
PMID: 15861359
Tularemia is a zoonotic infection that has rarely been reported in transplant recipients. The authors present a case of unsuspected tularemia in a kidney transplant patient that was diagnosed by...
7.
Brennan D, Agha I, Bohl D, Schnitzler M, Hardinger K, Lockwood M, et al.
Am J Transplant
. 2005 Feb;
5(3):582-94.
PMID: 15707414
Our purposes were to determine the incidence of BK viruria, viremia or nephropathy with tacrolimus (FK506) versus cyclosporine (CyA) and whether intensive monitoring and discontinuation of mycophenolate (MMF) or azathioprine...